AllSci News
Pharvaris advances first bradykinin B2 antagonist for on-demand HAE treatment to FDA review
Pharvaris N.V. (Nasdaq: PHVS) has submitted a New Drug Application to the US FDA for deucrictibant immediate-release (IR) capsule (20 mg) for the on-demand...
MGI Tech's ProtoPilot closes the gap between AI reasoning and wet-lab execution
MGI Tech's subsidiary Genoria AI, in partnership with the Shanghai Artificial Intelligence Laboratory, launched ProtoPilot and BioLab Bench on July 5 — a...
Henry Ford Health secures NIH funding for inhaled IPF therapy based on vonoprazan
Henry Ford Health + Michigan State University Health Sciences has received a USD 1.56 million NIH R01 grant from the National Heart, Lung, and Blood...
VCU advances dual EGFR/HER2 degradation strategy to overcome drug resistance in lung cancer
Virginia Commonwealth University has received a USD 1.74 million National Cancer Institute R01 award to advance preclinical evaluation of PEPDG278D, a...
Broad Institute advances gene editing to permanently lower prion protein and halt neurodegeneration
The Broad Institute has received a USD 11.3 million NIH U19 renewal to advance gene editing approaches aimed at permanently lowering prion protein (PrP)...
Aureka open-sources biomolecular foundation model for AI drug discovery
Laguna Hills, California-based Aureka has released OpenDDE, an open-source, all-atom biomolecular foundation model designed to serve as a structural...
Beckman Coulter's CE-marked p-Tau217 blood test enables scalable Alzheimer's screening in routine labs
Beckman Coulter Diagnostics has received CE Mark under IVDR for its Access p-Tau217 blood test and simultaneously unveiled a companion research assay, the...
China's CDE launches PIONEER Program to advance NAMs in drug development
Category: Science & Innovation Policy | Regulatory Body: CDE (Center for Drug Evaluation, NMPA) | Geography: China | Instrument: Initiative launch
Cyllene Therapeutics secures EUR 33m Series C to advance HSV-based genetic medicine platform
France-based Cyllene Therapeutics, formerly known as EG 427, has closed a EUR 33 million Series C financing round to advance clinical development of EG110A,...
Vertex bets USD 10b on endocrinology diversification with Crinetics acquisition
Vertex Pharmaceuticals has agreed to acquire San Diego-based Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) for USD 85.00 per share in cash, representing a...
Agenus posts three-year survival data for botensilimab in MSS colorectal cancer
Agenus Inc. (Nasdaq: AGEN) reported three-year overall survival data from its Phase Ib C-800-01 trial at ESMO GI 2026 in Munich, showing that 33% of...
Incyte completes USD 2b Vega acquisition for VWD antibody
Incyte (Nasdaq: INCY) has completed its acquisition of Vega Therapeutics, Inc., a wholly owned subsidiary of San Francisco-based Star Therapeutics LLC,...
OS Therapies seeks FDA alignment on survival endpoint for osteosarcoma gene therapy
OS Therapies, Inc. (NYSE American: OSTX) has requested a Type B meeting with the US FDA to resolve a central unresolved question…
Multitude presents early clinical validation for CDH17 ADC in colorectal cancer
Interim Phase I data from China-based Multitude Therapeutics reported a 20% overall response rate and a 91% disease control rate for AMT-676, a...
HutchMed’s Orpathys becomes first MET inhibitor approved for gastric cancer in China
HutchMed (China) Limited (Nasdaq: HCM) has received conditional NMPA approval for Orpathys (savolitinib) as the first selective MET inhibitor indicated for locally…
The AllSci Brief
Systematic R&D and deal news. Daily.